Cargando…
The Emerging Potential of Parthenolide Nanoformulations in Tumor Therapy
Plant-derived sesquiterpene lactones are promising natural sources for the discovery of anti-cancer drugs. As an extensively studied sesquiterpene lactone, the tumor suppression effect of parthenolide (PTL) has been clarified by targeting a number of prominent signaling pathways and key protein regu...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063801/ https://www.ncbi.nlm.nih.gov/pubmed/35517982 http://dx.doi.org/10.2147/DDDT.S355059 |
_version_ | 1784699239170834432 |
---|---|
author | An, Tao Yin, Huanhuan Lu, Yanting Liu, Feng |
author_facet | An, Tao Yin, Huanhuan Lu, Yanting Liu, Feng |
author_sort | An, Tao |
collection | PubMed |
description | Plant-derived sesquiterpene lactones are promising natural sources for the discovery of anti-cancer drugs. As an extensively studied sesquiterpene lactone, the tumor suppression effect of parthenolide (PTL) has been clarified by targeting a number of prominent signaling pathways and key protein regulators in carcinogenesis. Notably, PTL was also the first small molecule reported to eradicate cancer stem cells. Nevertheless, the clinical application of PTL as an antitumor agent remains limited, owing to some disadvantages such as low water solubility and poor bioavailability. Thus, nanomedicine has attracted much interest because of its great potential for transporting poorly soluble drugs to desired body sites. In view of the significant advantages over their free small-molecule counterparts, nanoparticle delivery systems appear to be a potential solution for addressing the delivery of hydrophobic drugs, including PTL. In this review, we summarized the key anticancer mechanisms underlined by PTL as well as engineered PTL nanoparticles synthesized to date. Therefore, PTL nanoformulations could be an alternative strategy to maximize the therapeutic value of PTL. |
format | Online Article Text |
id | pubmed-9063801 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-90638012022-05-04 The Emerging Potential of Parthenolide Nanoformulations in Tumor Therapy An, Tao Yin, Huanhuan Lu, Yanting Liu, Feng Drug Des Devel Ther Review Plant-derived sesquiterpene lactones are promising natural sources for the discovery of anti-cancer drugs. As an extensively studied sesquiterpene lactone, the tumor suppression effect of parthenolide (PTL) has been clarified by targeting a number of prominent signaling pathways and key protein regulators in carcinogenesis. Notably, PTL was also the first small molecule reported to eradicate cancer stem cells. Nevertheless, the clinical application of PTL as an antitumor agent remains limited, owing to some disadvantages such as low water solubility and poor bioavailability. Thus, nanomedicine has attracted much interest because of its great potential for transporting poorly soluble drugs to desired body sites. In view of the significant advantages over their free small-molecule counterparts, nanoparticle delivery systems appear to be a potential solution for addressing the delivery of hydrophobic drugs, including PTL. In this review, we summarized the key anticancer mechanisms underlined by PTL as well as engineered PTL nanoparticles synthesized to date. Therefore, PTL nanoformulations could be an alternative strategy to maximize the therapeutic value of PTL. Dove 2022-04-29 /pmc/articles/PMC9063801/ /pubmed/35517982 http://dx.doi.org/10.2147/DDDT.S355059 Text en © 2022 An et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review An, Tao Yin, Huanhuan Lu, Yanting Liu, Feng The Emerging Potential of Parthenolide Nanoformulations in Tumor Therapy |
title | The Emerging Potential of Parthenolide Nanoformulations in Tumor Therapy |
title_full | The Emerging Potential of Parthenolide Nanoformulations in Tumor Therapy |
title_fullStr | The Emerging Potential of Parthenolide Nanoformulations in Tumor Therapy |
title_full_unstemmed | The Emerging Potential of Parthenolide Nanoformulations in Tumor Therapy |
title_short | The Emerging Potential of Parthenolide Nanoformulations in Tumor Therapy |
title_sort | emerging potential of parthenolide nanoformulations in tumor therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063801/ https://www.ncbi.nlm.nih.gov/pubmed/35517982 http://dx.doi.org/10.2147/DDDT.S355059 |
work_keys_str_mv | AT antao theemergingpotentialofparthenolidenanoformulationsintumortherapy AT yinhuanhuan theemergingpotentialofparthenolidenanoformulationsintumortherapy AT luyanting theemergingpotentialofparthenolidenanoformulationsintumortherapy AT liufeng theemergingpotentialofparthenolidenanoformulationsintumortherapy AT antao emergingpotentialofparthenolidenanoformulationsintumortherapy AT yinhuanhuan emergingpotentialofparthenolidenanoformulationsintumortherapy AT luyanting emergingpotentialofparthenolidenanoformulationsintumortherapy AT liufeng emergingpotentialofparthenolidenanoformulationsintumortherapy |